688166 博瑞医药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.7077.9628.88012.38415.688
总资产报酬率 ROA (%)0.3263.7134.1786.28010.170
投入资产回报率 ROIC (%)0.3554.0194.5036.91011.259

边际利润分析
销售毛利率 (%)48.70857.51055.79463.01156.227
营业利润率 (%)-0.89712.49816.12923.80324.609
息税前利润/营业总收入 (%)2.73815.44718.05124.77125.009
净利润/营业总收入 (%)0.30811.01414.70320.78322.573

收益指标分析
经营活动净收益/利润总额(%)241.051114.473105.52296.612102.124
价值变动净收益/利润总额(%)76.515-11.026-8.0840.2323.892
营业外收支净额/利润总额(%)3.965-1.965-0.7810.021-0.597

偿债能力分析
流动比率 (X)1.3341.5591.9952.3881.703
速动比率 (X)1.0131.2121.6212.0431.360
资产负债率 (%)51.96452.95251.95451.90841.351
带息债务/全部投入资本 (%)47.09147.18447.83648.34135.207
股东权益/带息债务 (%)106.093106.877105.609105.323181.201
股东权益/负债合计 (%)88.44387.28590.60490.579136.663
利息保障倍数 (X)0.7464.8438.82025.71645.853

营运能力分析
应收账款周转天数 (天)99.37885.71789.395119.63694.175
存货周转天数 (天)240.629234.266215.752229.802157.568